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Abstract
Objective. To determine the minimum change of the Tinnitus 
Handicap Inventory (THI) score that could be considered 
clinically relevant, the authors compared the absolute change 
of the THI with the Clinical Global Impression–Improvement 
(CGI-I) score.
Study Design. International studies register with standardized 
data collection.
Setting. Tinnitus Research Initiative (TRI).
Subjects and Methods. Two hundred ten patients of the TRI da-
tabase were eligible for this study. In the first analysis, the THI 
score change and CGI-I ratings were compared with equipe-
rcentile linking. In a second analysis, the authors categorized 
the CGI-I into the 4 groups much better or better, minimally 
better, no change, and worse and calculated the corresponding 
differences of the THI score and the effect sizes. An effect 
size separating the minimally better and the no-change groups 
was chosen, and the referring THI mean score difference was 
calculated.
Results. According to the linking method, a CGI-I value of 3 
(minimally better) corresponded to a THI score reduction of 
6 to 16, whereas the CGI-I value of 4 (no change) corre-
sponded to the range between improvement by 5 points and 
worsening by 4 points. For separating the no-change and mini-
mally better groups, an effect size d = 0.5 was determined, re-
sulting in a minimal clinically relevant difference of ΔTHI = 7.
Conclusion. Two different methods yielded comparable results 
in identifying a reduction in the THI score of 6 and 7 points, 
respectively, as the minimal clinically relevant change. This 
study provides a first orientation for sample size calculations 
and for planning the design of future studies.
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Prospective placebo-controlled randomized trials are obligatory for proving the efficacy of new treatments. In the past few years, a large variety of new treatment 
options for tinnitus have been proposed, which has increased 
the need for clinical studies in this field. The most critical part 
in the design of clinical studies is the choice of outcome mea-
surements. In tinnitus research, the quantification of severity 
is challenging for many reasons. First, tinnitus is a purely sub-
jective sensation lacking objectively measurable variables. 
Second, tinnitus has many aspects and dimensions that vary 
from patient to patient. Some patients are most bothered by 
the loudness of their tinnitus, whereas others mainly suffer 
from tinnitus-related insomnia or concentration difficulties. 
Several approaches have been developed for the quantifica-
tion of tinnitus. Besides psychometric measures of tinnitus 
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loudness or minimal masking levels, visual analog scales and 
numeric rating scales of tinnitus loudness or annoyance have 
been used. Moreover, different standardized questionnaires 
for the assessment of tinnitus-related handicaps have been 
developed, validated, and translated into different languages. 
The situation is further complicated by the relatively low cor-
relation between the different assessment instruments.1 The 
best test-retest reliability and the best validity with quality of 
life have been shown for standardized tinnitus questionnaires.2 
However, none of these questionnaires has been developed for 
the assessment of treatment-related changes; furthermore, 
only limited data are available about what changes in the score 
can be considered clinically relevant.3
Knowledge about the minimal change in the score of a spe-
cific questionnaire that can be considered clinically relevant is 
important for both the interpretation and the design of clinical 
trials. One example is the estimation of the sample size, which 
determines the number of patients needed for a study to reject 
the null hypothesis and to confirm the alternative hypothesis (ie, 
to show that the new treatment has an effect) under a predefined 
alpha and beta level. For the calculation of the sample size, the 
most important information is the expected effect of the new 
treatment compared with placebo. The expected effect has to be 
both statistically different from placebo and clinically relevant. 
Information about clinically relevant changes is also needed for 
the interpretation of study results. A statistically significant 
score change may not necessarily be also clinically relevant.
The Tinnitus Handicap Inventory (THI) is probably the 
most widespread validated questionnaire for quantifying tin-
nitus severity.4 In recent prospective randomized studies, the 
THI has also been used as primary or secondary outcome 
measurements.5-8 Because of its widespread application, 
the THI has been recommended in a consensus document to 
be used as an outcome measurement in clinical trials to allow 
comparability across studies.2 With regard to the clinical rel-
evance of changes in the THI score, the only available orienta-
tion is the 95% confidence interval of 20 points, suggesting 
that a change of 20 points can be considered significant.9
To estimate clinically relevant changes, we analyzed data 
from the Tinnitus Research Initiative (TRI) database that contains 
changes in different tinnitus questionnaires from patients under-
going different treatment trials.10 Here, we compared changes in 
the THI with patients’ subjective impressions of treatment-related 
changes of tinnitus. The patents’ subjective impressions were 




Data from the TRI database were analyzed. The TRI database 
contains longitudinal data that are collected in a standardized 
way from patients undergoing different types of treatment 
interventions in different study centers and different coun-
tries.10 Data collection within the TRI database has been 
approved by the local ethics committee of the University of 
Regensburg, Germany.
Patient Inclusion and Exclusion Criteria
At the time of analysis, 320 patients from 6 different centers 
who had received 21 different forms of treatment, including 
behavioral therapy, pharmacologic treatment, and brain stim-
ulation, were included in the database. All data sets, including 
the THI at baseline and the THI and the CGI-I at the end of 
treatment, were included in the analysis. No exclusion criteria 
were defined.
A total of 210 patients met the inclusion criteria. The time 
interval between baseline and the end of treatment was 2 
weeks in 2 patients, 4 weeks in 109 patients, and 12 weeks in 
99 patients.
Assessments
The THI is a validated and widely used questionnaire for 
assessing the impact of tinnitus in daily life.4,12 The THI is 
also frequently used for documenting the treatment outcomes 
of tinnitus, even though the THI has not been developed and 
validated for this purpose. Besides the original English ver-
sion, translations into Danish, Spanish, Korean, Portuguese, 
German, Italian, and Chinese have been validated and pub-
lished.13-15 The THI consists of 25 items, each with the 3 
response options—yes (4 points), sometimes (2 points), and 
no (0 points)—resulting in a total score range from 0 to 100. 
A higher score denotes a higher tinnitus-related handicap.
To assess a patient’s subjective perception about the change 
of tinnitus over time, we applied a modified version of the 
CGI-I11 for use in tinnitus complaints. In this version, the 
patients themselves are asked to “rate the total improvement 
of their tinnitus complaints compared to before the beginning 
of treatment.” Patients had to mark 1 of the 7 answers: 1, very 
much better; 2, much better; 3, minimally better; 4, no change; 
5, minimally worse; 6, much worse; and 7, very much worse.
The THI and further questionnaires were filled in at base-
line as well as the CGI-I at all following visits (which had 
been 1 to 4 visits over 2 to 16 weeks, depending on the type of 
treatment), including the end of therapy and follow-up. An 
example about the collected data for a specific treatment can 
be found in Landgrebe et al.10
Statistical Analysis
Patient characteristics are summarized by means of median 
values and interquartile ranges (first to third quartiles) for 
continuous variables, as well as frequency counts and per-
centages for categorical data. For comparison of 2 continuous 
variables, the Student t test for independent and dependent 
variables was applied; for 3 or more groups, we used the 
1-way analysis of variance (ANOVA) test.
To analyze changes in the THI score, we favored the abso-
lute score change over the percentage score change for the 
following reasons: our analyses showed that the absolute 
score change is less dependent on baseline than the percentage 
score change and is therefore more appropriate for future 
covariance analyses.16 Also, for planning clinical trials with 
the THI score as the primary outcome, the expected absolute 
score change is easier to estimate than the percentage score 
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change because it is less dependent on the baseline values of 
the study population, which can range from 0 to 100.
Spearman rank correlation was calculated for a compari-
son of the patients’ CGI-I scores at the end of treatment with 
the changes of the THI scores.17 Furthermore, 2 different 
methods were used to get a reliable answer to which change 
in the THI score patients perceive as an at least minimal 
improvement.
Equipercentile Linking
To examine the link between CGI-I and the absolute change 
of the THI score, we used equipercentile linking, a method 
identifying those scores on both measures with the same per-
centile rank.18 This method has the advantage that, unlike in 
linear regression models, no linearity needs to be assumed. 
Linear regression would not be an appropriate method 
because both variables are measured with random error, and 
the task is not to predict one variable using the other but to 
concord both variables. Equipercentile linking has been suc-
cessfully applied in different fields of psychiatry19-21 and 
psychology.22 For our calculations, we applied the SAS macro 
EQUIPERCENTILE,23 a realization of the algorithms described 
by Kolen and Brennan.18
Cohen Effect Size d
We used Cohen effect size d for dependent variables to esti-
mate the effects of the THI score change within different 
groups according to the CGI-I scores and to recommend a 
patient-relevant THI score change.24 For calculation of the 
effect size, we used the following formula:
d =
 mx - my
     σ2 pooled
where µx and µy are the mean values of baseline and the end 
of treatment, and σ2 pooled  is the pooled standard deviation.
For a better interpretation of size and direction of the calcu-
lated effect sizes, the absolute value in the numerator was left 
out.
The corresponding 95% confidence intervals for each 
effect size were calculated according to Smithson.25
For analysis, different groups with regard to the CGI-I 
scores were formed:
Much better: CGI-I < 3
Minimally better: CGI-I = 3
No change: CGI-I = 4
Worse: CGI-I > 4.
To find a minimal clinical and therefore patient-relevant 
difference in the change of the THI score, the 2 important 
groups were minimally better and no change, which present 
the smallest difference between no treatment effect and small 
treatment effect. The other 2 groups only served as control 
groups because they should show a more extreme effect in the 
change of the THI score.
The effect sizes and the appropriate confidence intervals 
were calculated for all subgroups. Afterward, the effect sizes 
of the minimally better and no-change groups were compared, 
and an effect size, which separates them, was chosen. To esti-
mate an appropriate standard deviation of the THI difference 
in clinical studies, we calculated the mean overall standard 
deviations of all studies with more than 4 patients. Together 
with the chosen effect size, we calculated the corresponding 
change of the THI score. As a rough rule of thumb, the effect 
size of Cohen can be categorized into small effect (around 0.2-
0.3), medium effect (around 0.5), and large effect (around 0.8 
to infinity).
Statistical analyses were done with PASW 18.0 (SPSS, an 




Two hundred ten patients from Argentina, Belgium, Brazil, 
and Germany, aged between 16 and 88 years (median 54.6 
years, interquartile range [IQR], 44.6-63.0 years), were 
included in this study; the tinnitus duration was between 3 
months and 44 years (median 5.2 years; IQR, 1.9-11.1 years). 
Baseline characteristics and other tinnitus-related information 
are presented in Table 1.
Table 1. Patient Characteristics at Baseline (N = 210)
Age, y, median (IQR) 54.6 (44.6-63.0)
Tinnitus duration, y, median (IQR) 5.2 (1.9-11.1)
Sex, No. (%)a  
 Male 134 (63.8)
 Female 76 (36.2)
Laterality, No. (%)a
 Right 55 (26.2)
 Left 77 (36.7)
 Both sides/inner head 75 (35.7)
Tinnitus severity at baseline based on the THI, No. (%)a
 Slight 17 (8.1)
 Mild 70 (33.3)
 Moderate 65 (31.0)
 Severe 41 (19.5)
 Catastrophic 17 (8.1)
Etiology, No. (%)a
 Blast trauma 24 (11.4)
 Injury of cervical spine 3 (1.4)
 Change of hearing 17 (8.1)
 Stress 56 (26.7)
 Head injury 6 (2.9)
 Other 100 (47.6)
Type of treatment, No. (%)a
 Pharmaceutical drugs 145 (59.5)
 Transcranial direct current stimulation 22 (10.5)
 Repetitive transcranial magnetic stimulation 43 (30.0)
Abbreviations: IQR, interquartile range; THI, Tinnitus Handicap Inventory.
aPercentages do not add up to 100% because of occasional missing values.
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Analysis of THI and CGI-I Scores
The THI mean (SD) score at baseline was 45.0 (21.3) and 
37.4 (23.6) at the end of therapy, resulting in a significant 
mean change of 7.6 points (P < .001, 95% confidence interval 
[CI], 5.3-9.7). The frequency distribution of the CGI-I at the 
end of therapy is shown in Table 2 together with the corre-
sponding THI mean change and the duration of tinnitus since 
initial onset. No significant difference exists in the duration of 
tinnitus for each CGI-I value, but the differences in the THI 
mean change are highly significant (P < .001). The distribu-
tions of the change of the THI score, categorized by the CGI 
at the last day of therapy, are shown in Figure 1. The correla-
tion coefficient between the THI mean change and the CGI-I 
according to Spearman is r = 0.45 (P < .001).
Linking the CGI-I Score and the Absolute 
Change of the THI from Baseline to the End of 
Treatment
The THI absolute score change from baseline to the end of 
treatment and the CGI-I score at the end of treatment were 
linked and are presented in Figure 2. The scores were linked 
as follows: feeling “very much worse” on the CGI (CGI-I 
score 7) corresponded to a THI score change of –30 to –26, 
“much worse” (CGI-I score 6) corresponded to a THI score 
change of –25 to –17, “minimally worse” (CGI-I score 5) cor-
responded to a THI score change of –16 to –5, “no change” 
(CGI-I score 4) corresponded to a THI score change of –4 to 
5, “minimally better” (CGI-I score 3) corresponded to a THI 
score change of 6 to 16, “much better” (CGI-I score 2) cor-
responded to a THI score change of 17 to 40, and “very much 
better” (CGI-I score 1) corresponded to a THI score change of 
41 to 66.
Combination of CGI-I Scores and Changes in 
THI Scores
According to the 4 groups—much better (CGI-I < 3), mini-
mally better (CGI-I = 3), no change (CGI-I = 4), and worse 
(CGI-I > 4)—the direction, magnitude, and variation of the 
changes in the THI scores between baseline and the end of 
therapy are summarized by effect sizes according to Cohen 
d. For calculation of an effect size, mean and pooled standard 
deviation of the difference between THI at baseline and THI 
at the last visit are needed for each group. The effect sizes of 
all groups are summarized in Table 3. The effect size of the 
minimally better group (CGI = 3) is 0.74 (95% CI, 0.42-1.05) 
and that of patients with no change (CGI = 4) is 0.26 (0.03-
0.48). Although the confidence intervals are wide because of 
the relative small sample sizes and large standard deviations 
for each group, a notable difference can be seen between the 
2 groups with only a small range (0.42-0.48) of the 95% con-
fidence intervals overlapping.
The cutoff point, which separates the no-change group 
(CGI = 4) from the minimally better group (CGI = 3), has to 
be outside the 95% confidence interval of the CGI = 4 group 
and should also represent a minimal acceptable effect size to 
favor the CGI = 3 group. Therefore, an effect size of d = 0.5 
(>0.48) is an acceptable choice, which is also the approximate 








Very much better 11 (5.2) 30.4 (21.4) 6.8 (7.1)
Much better 37 (17.6) 16.6 (18.1) 7.9 (8.8)
Minimally better 49 (23.3) 9.5 (12.9) 8.4 (9.9)
No change 78 (37.1) 3.2 (12.7) 9.1 (8.9)
Minimally worse 27 (12.9) −2.3 (10.4) 9.1 (9.3)
Much worse 7 (3.3) −3.2 (12.6) 11.8 (14.5)
Very much worse 1 (0.5) -2 (—) 2.3 (—)
aΔTHI: Tinnitus Handicap Inventory (THI) at baseline – THI at last day of 
therapy.
Figure 1. Boxplots of Tinnitus Handicap Inventory (THI) score 
change categorized by the Clinical Global Impression–Improvement 
(CGI-I) score at the end of treatment.
Figure 2. Linking the Clinical Global Impression–Improvement 
(CGI-I) score with Tinnitus Handicap Inventory (THI) total score 
change.
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difference of the estimated effect sizes of the 2 groups (Figure 
3). An effect size of d = 0.5 is also in line with the “universal-
ity of half a standard deviation” in the interpretation of changes 
of quality-of-life data.26 In addition to the effect size, an esti-
mated standard deviation of the before-after difference of the 
THI score is needed. The mean pooled standard deviation of 
all used studies with n ≥ 5 is SD
diff
 = 13.8≈14. With an effect 
size of d = 0.5 and an estimated standard deviation of the 
before-after difference of the THI score of SD
diff
 = 14, the 
change of the THI score can be calculated to ΔTHI = 7.
Discussion
The attempt to determine minimal clinically important differ-
ences has been made in various assessment areas, such as 
quality of life,27,28 depression,29 schizophrenia,21 and pain 
severity.30 The basic approach for most of these studies is to 
reference the change of the instrument scores to a categorical 
rating of changes in patients’ health status. According to this 
approach, by using the CGI-I as the self-assessment of the 
current health status, we investigated the size of a meaningful 
change in the THI score.
The present study suggests that a minimum clinically sig-
nificant change in the THI score can be defined by a before-
after difference of 7 points, based on a calculated effect size of 
d = 0.5 and an estimated standard deviation of the THI mean 
score change in clinical studies of SD
Diff
 = 14. This definition is 
also in agreement with the linking method, calculating that a 
THI score change of 6 to 16 points corresponds with a CGI-I 
score of 3 (minimally better), and a THI score change of –4 to 5 
corresponds with a CGI-I score of 4 (no change). Thus, both 
statistical methods show that patients perceive a THI score 
reduction of at least 7 points as an improvement. Furthermore, 
the equilinkage method indicates that a reduction of 17 points 
or more is perceived as a highly relevant improvement (much 
better). These data suggest a reduction of 7 points in the THI as 
a meaningful response criterion in clinical trials. A reduction of 
17 points could be used as a criterion for a “super response.”
We are well aware that this analysis does not account for 
possible covariables, such as the THI baseline score, age, eti-
ology, duration of tinnitus, or type of treatment. All these fac-
tors may influence the subjective perception of how tinnitus is 
changing over time. For example, elderly patients with a 
10-year history of tinnitus will rate their improvement of tin-
nitus complaints rather differently than younger patients who 
have had tinnitus just for several months. Unfortunately, the 
sample size of this study did not allow us to analyze the role 
of these potential covariables. Therefore, further studies with 
larger samples are needed to confirm our findings and to eval-
uate the role of potentially influencing factors.
Conclusion
This study serves as an orientation of what difference in the 
THI score corresponds to a clinically meaningful improve-
ment in individual patients. Further analyses from larger and 
independent samples are needed to cross-validate and confirm 
this result. Furthermore, the role of potential influencing fac-
tors, such as the THI baseline score, age, etiology, or the dura-
tion of tinnitus, should be investigated.
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